Next GEN Act of 2026 Next Generation Medicines Act of 2026
To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.
The Next GEN Act of 2026 aims to change the rules for certain engineered cyclic peptides that qualify as single-source drugs in the Drug Price Negotiation Program. These changes are meant to impact how drug prices are negotiated under the Social Security Act.
This bill would affect pharmaceutical companies and patients by potentially altering the eligibility of certain drugs for price negotiations. It could influence how much patients pay for medications and how drug companies set prices. However, the exact impacts depend on the final language of the bill after it goes through the legislative process.
HB8857 was introduced on May 15, 2026, and has been referred to the Committee on Energy and Commerce and the Committee on Ways and Means for further consideration. It is currently in the initial stages of the legislative process, and no further actions have been taken yet.
